ambulatory treatment of type 2 diabetes in the u.s., 1997–2012 featured article: lydia w. turner,...
TRANSCRIPT
![Page 1: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/1.jpg)
Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012
Featured Article:
Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, andG. Caleb Alexander
Diabetes Care Volume 37: 985-992
April, 2014
![Page 2: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/2.jpg)
STUDY OBJECTIVE
• Study examines trends in the patterns and costs of drug treatment of type 2 diabetes from 1997 to 2012
Turner et al. Diabetes Care 2014;37:985-992
![Page 3: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/3.jpg)
STUDY DESIGN AND METHODS
• Descriptive analyses were conducted of cross-sectional data using the IMS Health National Disease and Therapeutic Index
• Focus was on diabetes patients ≥35 years of age
• IMS Health National Prescription Audit of pharmacy dispensing was used to derive information about drug expenditures
Turner et al. Diabetes Care 2014;37:985-992
![Page 4: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/4.jpg)
Turner et al. Diabetes Care 2014;37:985-992
![Page 5: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/5.jpg)
RESULTS
• Ambulatory diabetes visits increased from 23 million treatment visits in 1997 to 35 million in 2007 and declined to 31 million visits by 2012
• Between 1997 and 2012, biguanide use increased, from 23% to 53% of treatment visits
• Glitazone use grew from 6% in 1997 (41% of all visits in 2005), but declined to 16% by 2012
Turner et al. Diabetes Care 2014;37:985-992
![Page 6: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/6.jpg)
RESULTS
• Since 2005, dipeptidyl peptidase-4 (DPP-4) inhibitor use increased steadily, representing 21% of treatment visits by 2012
• Glucagon-like peptide 1 (GLP-1) agonists accounted for 4% of treatment visits in 2012
• Visits where two or more drug compounds were used increased nearly 40% from 1997 to 2012
• Between 2008 and 2012, drug expenditures increased 61%, driven primarily by use of insulin glargine and DPP-4 inhibitors
Turner et al. Diabetes Care 2014;37:985-992
![Page 7: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/7.jpg)
Turner et al. Diabetes Care 2014;37:985-992
![Page 8: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/8.jpg)
Turner et al. Diabetes Care 2014;37:985-992
![Page 9: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/9.jpg)
Turner et al. Diabetes Care 2014;37:985-992
![Page 10: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/10.jpg)
Turner et al. Diabetes Care 2014;37:985-992
![Page 11: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/11.jpg)
Turner et al. Diabetes Care 2014;37:985-992
![Page 12: Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G](https://reader038.vdocuments.site/reader038/viewer/2022110321/56649cdb5503460f949a612a/html5/thumbnails/12.jpg)
CONCLUSIONS
• Declining sulfonylurea and glitazone use has been offset by increases in DPP-4 inhibitor use and, to a lesser degree, use of GLP-1 agonists
• Treatment of diabetes has grown in complexity, while older treatments continue to be replaced or supplemented by newer therapies
Turner et al. Diabetes Care 2014;37:985-992